Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.58 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197380 | 0.92 | DGAT1 (0.59) | DGAT1SOAT1SOAT2PREPKDR | |
| SCHEMBL10197379 | 0.83 | DGAT1 (0.65) | DGAT1SOAT1SOAT2PREPCNR1 | |
| SCHEMBL10198038 | 0.83 | DGAT1 (0.72) | DGAT1SOAT1SOAT2 | |
| SCHEMBL409812 | 0.83 | DGAT1 (0.72) | DGAT1SOAT1SOAT2 | |
| SCHEMBL409813 | 0.83 | DGAT1 (0.72) | DGAT1SOAT1SOAT2 | |
| SCHEMBL10197337 | 0.82 | DGAT1 (0.83) | DGAT1SOAT1SOAT2PREPKDR | |
| SCHEMBL10197360 | 0.81 | DGAT1 (0.62) | DGAT1SOAT1SOAT2PREPCNR1 | |
| SCHEMBL10197400 | 0.81 | DGAT1 (0.62) | DGAT1SOAT1SOAT2PREPCNR1 | |
| SCHEMBL10197359 | 0.81 | DGAT1 (0.66) | DGAT1SOAT1SOAT2PREPKDR | |
| SCHEMBL13190530 | 0.81 | DGAT1 (0.54) | DGAT1SOAT1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT1 18/4885SOAT2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.